(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...

Respiratory syncytial virus (RSV) infections are the leading cause of viral death in infants, although RSV-related mortality has decreased since the development and approval of prophylactic ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Health officials are reminding the public that antibiotics are ineffective against respiratory infections caused by viruses, ...

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Timely diagnosis of RSV is imperative for optimal patient management; by rapidly identifying RSV infection, health professionals can implement appropriate infection control measures while limiting ...

Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...

For the last three years, health care providers have warned of a "tripledemic," during which rising cases of COVID-19, the flu and respiratory syncytial virus, or RSV, potentially burden ...

As the 2024-2025 respiratory virus season gets under way, statewide infectious disease experts urge everyone in Oregon to ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

Respiratory illnesses like influenza, COVID-19 and Respiratory Syncytial Virus (RSV) are known to spread more rapidly during ...